DGAP-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Miscellaneous Fresenius expects meaningful positive effects from US tax reform The new legislation triggers the revaluation of deferred tax liabilities. This results in a one-time book gain of approximately EUR 90 million, to be reflected in Fresenius' 2017 Group net income*. Thereof, approximately EUR 30 million are attributable to Fresenius Kabi and approximately EUR 60 million** to Fresenius Medical Care. Fresenius will report FY17 results and provide FY18 guidance, including details on recurring tax effects resulting from the US tax reform, on February 27, 2018.
Fresenius SE & Co. KGaA, Bad Homburg v.d.H., 22 December 2017
* Net income attributable to shareholders of Fresenius SE & Co. KGaA
-------------------------------
Markus Georgi
22-Dec-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Fresenius SE & Co. KGaA |
Else-Kröner-Straße 1 | |
61352 Bad Homburg v.d.H. | |
Germany | |
Phone: | +49 (0)6172 608-2485 |
Fax: | +49 (0)6172 608-2488 |
E-mail: | ir-fre@fresenius.com |
Internet: | www.fresenius.com |
ISIN: | DE0005785604 |
WKN: | 578560 |
Indices: | DAX |
Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxemburg |
End of Announcement | DGAP News Service |
641757 22-Dec-2017 CET/CEST